Roundup

Five things for pharma marketers to know: Friday, September 21, 2018

By

Alison Kanski

Publish Date September 21, 2018

Federal prosecutors investigate pharma kickbacks; FDA to fast-track e-cigarette designed to curb teen use; Medtronic to acquire Mazor Robotics.

Five things for pharma marketers to know: Thursday, September 20, 2018

By

Carrie Gavit

Publish Date September 20, 2018

Amicus acquires rare disease gene therapy programs; Data shows black patients are underrepresented in clinical trials; Takeda acquires Molecular Templates.

Five things for pharma marketers to know: Wednesday, September 19, 2018

By

Alison Kanski

Publish Date September 19, 2018

AbbVie accused of kickbacks to push Humira; Opioid crisis becomes major midterm campaign theme; GSK hires former Boehringer Ingelheim chief medical officer.

Five things for pharma marketers to know: Tuesday, September 18, 2018

By

Laura Entis

Publish Date September 18, 2018

Senate overwhelmingly passes opioid bill; Novo Nordisk plans layoffs in Denmark, China; Justice Department OKs Cigna’s acquisition of Express Scripts.

Five things pharma marketers need to know: Monday, September 17, 2018

By

Laura Entis

Publish Date September 17, 2018

Gottlieb outlines reimbursement reforms for antimicrobial treatments; Teva’s migraine treatment wins FDA approval; Study finds daily low-dose aspirin risks for older individuals.

Five things for pharma marketers to know: Thursday, September 13, 2018

By

Carrie Gavit

Publish Date September 13, 2018

Nostrum CEO blames FDA for 400% price hike; Boehringer Ingelheim acquires biotech ViraTherapeutics; Scientists make breakthrough discovery with BRCA1 gene.

Five things for pharma marketers to know: Wednesday, September 12, 2018

By

Alison Kanski

Publish Date September 12, 2018

FDA threatens to ban flavored vapes; Cigna launches $250 million venture fund; Takeda shutters Chicago operations.

Five things for pharma marketers to know: Tuesday, September 11, 2018

By

Laura Entis

Publish Date September 11, 2018

Nostrum CEO defends decision to hike antibiotic price; Appeals court rules Acorda patents for Ampyra are not valid; University patent battle over gene-editing technology concludes.

Five things for pharma marketers to know: Monday, September 10, 2018

By

Laura Entis

Publish Date September 10, 2018

U.K. regulator rules MS drug too expensive; Memorial Sloan Kettering CEO demands more transparency from staff on financial relationships; Report: Family behind Purdue owns second opioid drugmaker.

Five things for pharma marketers to know: Friday, September 7, 2018

By

Carrie Gavit

Publish Date September 7, 2018

Opioid-treatment patent award raises concerns; Senate to vote on opioid bill next week; Walgreens stocks up on Auvi-Q.

Five things for pharma marketers to know: Thursday, September 6, 2018

By

Carrie Gavit

Publish Date September 6, 2018

Justice Department closer to merger approvals; GSK cuts 650 jobs; Civica Rx names CEO.

Five things for pharma marketers to know: Wednesday, September 5, 2018

By

Alison Kanski

Publish Date September 5, 2018

Comcast veteran joins Amazon, Berkshire, JP Morgan health venture; Theranos to dissolve; Bayer mulls job cuts in R&D review.

Five things for pharma marketers to know: Tuesday, September 4, 2018

By

Laura Entis

Publish Date September 4, 2018

Caplacizumab wins European approval; former Glaxo scientist pleads guilty to trade secret theft charge; FDA to hold hearing on boosting biologic competition.

Five things for pharma marketers to know: Friday, August 31, 2018

By

Carrie Gavit

Publish Date August 31, 2018

AstraZeneca’s lupus drug fails to meet goals; FDA expands investigation into heart drugs; Lilly names new head of Oncology.

Five things for pharma marketers to know: Thursday, August 30, 2018

By

Alison Kanski

Publish Date August 30, 2018

The first digital pill is rolling out to Medicaid patients; Narcan’s new owner sees an untapped market in schools; Medicare plans can decide which drug indication is covered.